Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice

Antiviral Research

Volumn 29, Issue 2-3, 1996, Pages 233-241

  Yang, Hyekyung ^a   Drain, Rebecca L ^a   Franco, Christine A ^a   Clark, Junius M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

antiviral; cyclobutylguanine; immunocompromised host; LP BM5 retrovirus complex; murine cytomegalovirus; nucleoside

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; LOBUCAVIR; NUCLEOSIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; FEMALE; IMMUNE DEFICIENCY; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTECTION; RETROVIRUS; SCID MOUSE; VIRUS TITRATION;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0029864703     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00901-9     Document Type: Article

References (32)

1. Braitman, A., Swerdel, M.R., Olsen, S.J., Tuomari, A.V., Lynch, J.S., Blue, B., Michalik, T., Field, A.K., Bonner, D.P. and Clark, J.M. (1991) Evaluation of SQ 34 514: Pharmacokinetics and efficacy in experimental herpes virus infections in mice. Antimicrob. Agents Chemother. 35, 1464-1468.
2. Chachoua, A., Dieterich, D., Krasinski, K., Greene, J., Laubenstein, L., Weinz, J., Buhles, W. and Koretz, S. (1987) 9-(1,3-dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Ann. Intern. Med. 107, 133-137.
3. Clement, J.J. and Kern, E.R. (1991) Cyclobutyl compounds as antiviral agents. Transplant. Proc. 23 (Suppl.3), 159-161.
4. De Castro, L.M., Kern, E.R., De Clercq, E., Ghaffar, A., Mayer, E.P., Vogt, P.E. and Gangemi, J.D. (1991) Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res. 16, 101-114.
5. De Miranda, P., Burnette, T., Cederberg, D., Blum., M.R., Brodie, H.R. and Mills, J. (1986) Program Abstr. 26th Intersci. Conf. Antimicrob. Agents Chemother., Abstr. no. 566.
6. Faulds, D., and Heel, R.C. (1990) Ganciclovir, a review of its antiviral activity, pharmakokinetic properties and therapeutic efficacy in cytomegalovirus infection. Drugs 39, 597-638.
7. Field, A.K., Tuomari, A.V., McGeever-Rubin, B., Terry, B.J., Mazina, K.E., Haffey, M.L., Hagen, M.E., Clark, J.M., Braitman, A., Slusarchyk, W.A., Young, M.G. and Zahler, R. (1990) (±)-(1a,2b,2a)-9-[2,3-bis(hydroxymethyl)cyclobutyl]-guanine [(±)-BHCG or SQ 33054]: a potent and selective inhibitor of herpesviruses. Antiviral Res. 13, 41-52.
8. Gangemi, J.D., Cozens, R.M., De Clercq, E., Balzarini, J. and Hochkeppel, H.-K. (1989) 9-(2-phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob. Agents Chemother. 33, 1864-1868.
9. Hartley, J.W., Fredrickson, T.N., Yetter, R.A., Makino, M. and Morse III, H.C. (1989) Retrovirus-induced murine acquired immunodeficiency syndrome: Natural history of infection and differing susceptibility of inbred mouse strains. J. Virol. 63, 1223-1231.
10. Hudson, J.B. (1979) The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections. Arch. Virol. 62, 1-29.
11. Jacobson, M.A., de Miranda, P., Cederberg, D.M., Burnett, T., Cobb, E. et al. (1987) Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob. Agents Chemother. 31, 1251-1254
12. Kern, E.R. (1991) Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Transplant. Proc. 23 (Suppl.3), 152-155.
13. Kleinbaum, D.G., Kupper, L.L. and Morgenstern, H. (1982) Statistical inferences about effect measures: simple analysis, In: D.G. Kleinbaum, L.L. Kupper, and H. Morgenstern (Eds.), Epidemiologic research, pp. 288-291. Lifetime Learning Publications, Belmont, CA.
14. Laskin, O.L., Cederberg, D.M., Mills, J., Eron, L.J., Mildvan, D. and Spector, S.S. (1987) Ganciclovir for the treatment and suppression of serious infections caused by cytomegaloviruses. Am. J. Med. 83, 201-207.
15. Laughlin, C.A., Black, R.J., Feinberg, J., Freeman, D.J., Ramsey, J., Ussery, M.A. and Whitley, R.J. (1991) Resistance to antiviral drugs. ASM News 57, 514-517.
16. Lee, E.T. (1980) Nonparametric methods for comparing survival distributions, In: E.T. Lee (Ed.), Statistical methods for survival data analysis, pp. 123-127. Lifetime Learning Publications, Belmont, CA.
17. Macher, A.M., Reichert, C.M., Straus, S.E., Longo, D.L., Parillo, J., Lane, H.C., Fauci, A.S., Rook, A.H., Manischewitz, J. and Quinnan, G.V. (1983) Death in the AIDS patient: role of cytomegalovirus. N. Engl. J. Med. 309, 1454.
18. Morse III, H.C., Yetter, R.A. and Shearer, G.M. (1988) Murine models of immunosuppression in relation to AIDS. In: R.C. Gallo (Ed.), HTLV I, II, and III and related diseases. Martinez-Nijhoff, Boston.
19. Mosier, D.E., Yetter, R.A. and Morse III, H.C. (1985) Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J. Exp. Med. 161, 766-784.
20. Murray, J.F., Felton, C.P., Garay, S.M., Gottlieb, M.S., Hopewell, P.C., Stover, D.E. and Teirstein, A.S. (1984) Pulmonary complications of the acquired immunodeficiency syndrome. N. Engl. J. Med. 310, 1682-1688.
21. Myers, J.D., Flourney, N. and Thomas, E.D. (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 153, 478-488.
22. Navia, B., Cho, E., Petito, C.K. and Price, R.W. (1986) The AIDS dementia complex. II. Neuropathology. Ann. Neurol. 19, 525-535.
23. Neyts, J., Balzarini, J., Naesens, L. and De Clerq, E. (1992) Efficacy of (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J. Med. Virol. 37, 67-71.
24. Palestine, A.G. (1988) Clinical aspects of cytomegalovirus retinitis. Rev. Infect. Dis. 10 (Suppl.3), S515-S520.
25. Pattengale, P.K., Taylor, C.R., Twomey, P., Hill, S., Jonasson, J., Beardsley, T. and Hass, M. (1982) Immunopathology of B-cell lymphomas induced in C57BL/6 mice by dual tropic murine leukemia virus (MuLV). Amer. J. Pathol. 107, 362-377.
26. Petty, B.G., Saito, H., Summerill, R.S., Burgee, H., McDowell, J. and Stewart, M.B. (1994) Pharmakokinetics and bioavailability of BMS-180194 in asymptomatic HIV-and CMV-seropositive Volunteers. Abstract presented at the 7th Int. conf. Antiviral Res., February 27-March 4, 1994, Charleston, SC.
27. Rubin, R.H. (1990) Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12 (Suppl.7), S754-S766.
28. Smee, D.F., Morris, J.L.B., Leonhardt, J.A., Mead, J.R., Holy, A. and Sidwell, R.W. (1992) Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob. Agents Chemother. 39, 1837-1842.
29. Smee, D.F., Barnett, B.B., Sidwell, R.W., Reist, E.J. and Holy, A. (1995) Antiviral activities of wild-type and drug-resistant strains of murine cytomegalovirus. Antiviral Res. 26, 1-9.
30. Snider, W.D., Simpson, D.M., Nielson, S., Gold, J.W., Metrako, C.E. and Posner, J.B. (1983) Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann. Neurol. 14, 403-418.
31. Walmsley, S.L., Chew, E., Fanning, M.M., Read, S.E., Vellend, H., Salit, I. and Rachlis, A. (1988) Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J. Infect. Dis. 157, 569-572.
32. Yetter, R.A., Buller, R.M.L., Lee, J.S., Elkins, K.L., Mosier, D.E., Fredrickson, T.N. and Morse III, H.C. (1988) CD4+ T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS). J. Exp. Med. 168, 623-635.